Seeking Alpha

Johnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to...

Johnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to Risperdal, Invega, Natrecor and Omnicare (OCR).
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs